These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22490950)

  • 1. [Study on the treatment of dry eye with Loteprednol Etabonate].
    Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
    Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
    Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
    Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
    Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
    Kim EC; Choi JS; Joo CK
    Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ; Djalilian AR; Sanderson JP
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regression of lid-parallel conjunctival folds (LIPCOF) on topical treatment with Liposic Eye Gel--a pilot study].
    Höh H; Schwanengel M
    Klin Monbl Augenheilkd; 2006 Nov; 223(11):918-23. PubMed ID: 17131254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effects of Pyranoprofen on the mouse dry eye induced by topical medication of Benzalkonium Chloride].
    He H; Liu ZG; Lin ZR; Liu XC; He H; Xiao QG
    Zhonghua Yan Ke Za Zhi; 2012 Jan; 48(1):33-40. PubMed ID: 22490914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients.
    Altiparmak UE; Acar DE; Ozer PA; Emec SD; Kasim R; Ustun H; Duman S
    Eye (Lond); 2010 Jun; 24(6):1044-50. PubMed ID: 19834507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial.
    Lee H; Chung B; Kim KS; Seo KY; Choi BJ; Kim TI
    Am J Ophthalmol; 2014 Dec; 158(6):1172-1183.e1. PubMed ID: 25128594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats.
    Beyazyıldız E; Acar U; Beyazyıldız Ö; Pınarlı FA; Albayrak A; Uğurlu N; Tiryaki M; Delibaşi T
    J Ocul Pharmacol Ther; 2014 May; 30(4):306-12. PubMed ID: 24494746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.